reports
- Joan Sehim
OPmobility : OPM stands out in an ailing industry
In a troubled automotive industry, OPmobility (OPM) stands out for its strong outperformance, market share gains and a speech that is more reassuring than its peers. As evidenced by the recent Q3 results, OPM is currently benefiting from record orders, particularly in the USA, and still has several medium-term growth drivers (Tesla, lighting, hydrogen). Although profitability is limited, and a number of structural weaknesses remain (including low exposure in China), OPM nonethele...
- Joan Sehim
OPmobility : OPM se distingue dans une industrie en difficulté
Dans une industrie automobile en difficulté, OPmobility (OPM) se distingue par une surperformance élevée, des gains de part de marché et un discours qui se veut plus rassurant que ses pairs. Comme l’atteste le récent T3, OPM profite aujourd’hui des commandes records passées, particulièrement aux USA, et dispose toujours de plusieurs leviers de croissance à moyen—terme (Tesla, éclairage, hydrogène). La profitabilité est certes limitée, et quelques faiblesses structurelles perduren...
EQS-News: Abivax Establishes an At-the-Market (ATM) Program on Nasdaq
EQS-News: ABIVAX / Key word(s): Miscellaneous Abivax Establishes an At-the-Market (ATM) Program on Nasdaq 19.11.2024 / 22:30 CET/CEST The issuer is solely responsible for the content of this announcement. Abivax Establishes an At-the-Market (ATM) Program on Nasdaq PARIS, France, November 19, 2024 – 10:30PM CET – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq - ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the inflammatory response in p...
Abivax Establishes an At-the-Market (ATM) Program on Nasdaq
Abivax Establishes an At-the-Market (ATM) Program on Nasdaq Abivax Establishes an At-the-Market (ATM) Program on Nasdaq PARIS, France, November 19, 2024 – 10:30PM CET – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq - ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the inflammatory response in patients with chronic inflammatory diseases, today announced the implementation of an At-The-Market program (“ATM Program”) allowing the Company to issue and sell, i...
EQS-News: Abivax presents third quarter 2024 key financial information
EQS-News: ABIVAX / Key word(s): Quarter Results Abivax presents third quarter 2024 key financial information 14.11.2024 / 22:01 CET/CEST The issuer is solely responsible for the content of this announcement. Abivax presents third quarter 2024 key financial information PARIS, France, November 14, 2024, 10:00 p.m. CET – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq – ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the inflammatory respon...
Abivax presents third quarter 2024 key financial information
Abivax presents third quarter 2024 key financial information Abivax presents third quarter 2024 key financial information PARIS, France, November 14, 2024, 10:00 p.m. CET – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq – ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the inflammatory response in patients with chronic inflammatory diseases, announces today its key financial information for the quarter ended September 30, 2024. Abivax provided the...
- Thijs Berkelder
- Usama Tariq
ODDO BHF Small & MIDCAP MORNING NEWS - Date1
We initiate coverage of Heijmans, a contractor focused on the Dutch market, with an Outperform rating and a TP of € 36.5 (DCF based). The Dutch residential market is finally recovering, and we believe Heijmans is well-positioned to benefit due to its land bank and property development arm, driving up revenues while EBITDA margins are expected to exceed 8.5% in the Living unit. Heijmans is also benefitting from strong demand from the infrastructure and energy markets, allowing for soli...
PBB DEUTSCHE PFANDBRIEFBANK AG
GBF BILFINGER SE
GYC GRAND CITY PROPERTIES SA
ITP INTERPARFUMS
SDF K+S AG
NEX NEXANS SA
IDIP INSTITUT DE DEVELOPPEMENT INDUSTRIEL SCA
ADN1 ADESSO AG
GNFT GENFIT SA
PAT PATRIZIA AG
SAX STROEER SE & CO. KGAA
NVG NAVIGATOR COMPANY SA
ASS APPLUS SERVICES S.A.
S92 SMA SOLAR TECHNOLOGY AG
CLA CLARANOVA SE
SRAIL STADLER RAIL AG
KTA KNAUS TABBERT
UPG UNIFIEDPOST GROUP
DEME DEME GROUP NV
AF AIR FRANCE - KLM
- Thijs Berkelder
- Usama Tariq
ODDO BHF Small & MIDCAP MORNING NEWS - 11/14/2024
We initiate coverage of Heijmans, a contractor focused on the Dutch market, with an Outperform rating and a TP of € 36.5 (DCF based). The Dutch residential market is finally recovering, and we believe Heijmans is well-positioned to benefit due to its land bank and property development arm, driving up revenues while EBITDA margins are expected to exceed 8.5% in the Living unit. Heijmans is also benefitting from strong demand from the infrastructure and energy markets, allowing for soli...
PBB DEUTSCHE PFANDBRIEFBANK AG
GBF BILFINGER SE
GYC GRAND CITY PROPERTIES SA
ITP INTERPARFUMS
SDF K+S AG
NEX NEXANS SA
IDIP INSTITUT DE DEVELOPPEMENT INDUSTRIEL SCA
ADN1 ADESSO AG
GNFT GENFIT SA
PAT PATRIZIA AG
SAX STROEER SE & CO. KGAA
NVG NAVIGATOR COMPANY SA
ASS APPLUS SERVICES S.A.
JST JOST WERKE AG
S92 SMA SOLAR TECHNOLOGY AG
CLA CLARANOVA SE
SRAIL STADLER RAIL AG
KTA KNAUS TABBERT
UPG UNIFIEDPOST GROUP
DEME DEME GROUP NV
AF AIR FRANCE - KLM
- Christophe-Raphaël Ganet
Interparfums : Feedback from the CMD: slight downward adjustment to es...
>Key takeaways: cautious guidance, less ambitious on Moncler and work to be done on enhancing the portfolio - 1/ Cautious guidance for 2025 (but the consensus too high), due to embedded effects. A good line-up for 2025: several launch initiatives are planned: Montblanc Explorer (new line), Jimmy Choo Man, Coach (2 new editions: Woman and Man), Solferino (new proprietary brand - niche perfumes / 10 lines listed in Paris for the story telling), Lacoste (extension of L12...
- Christophe-Raphaël Ganet
Interparfums : Feedback CMD : estimations légèrement abaissées
>Principaux éléments : guidance prudente, moins ambitieux sur Moncler et un travail à réaliser pour enrichir le portefeuille - 1/ Guidance 2025 prudente (mais CSS trop haut), compte tenu des effets embarqués. Bon line-up en 2025: plusieurs initiatives de lancements sont prévues : Montblanc Explorer (nouvelle ligne), Jimmy Choo Man, Coach (2 nouvelles déclinaisons : Woman et Man), Solferino (nouvelle marque propriétaire - parfums de niche / 10 lignes en référence à Par...
- Loic Morvan
Interparfums: cautious prospects for 2025
Interparfums management released cautious sales prospects for 2025 yesterday with limited growth despite the roll-out of Lacoste Original. Although we are slightly more aggressive than management, we have notched down our FY25 sales estimate from EUR960m to EUR950m. Buy reiterated with EUR54 vs EUR
EQS-News: Abivax Announces Former Prometheus COO, Mark Stenhouse, Appo...
EQS-News: ABIVAX / Key word(s): Personnel Abivax Announces Former Prometheus COO, Mark Stenhouse, Appointed as Board Observer & Advisor to Abivax 13.11.2024 / 22:01 CET/CEST The issuer is solely responsible for the content of this announcement. Abivax Announces Former Prometheus COO, Mark Stenhouse, Appointed as Board Observer & Advisor to Abivax PARIS, France, November 13, 2024, 10:00 pm CET – Abivax SA (Euronext Paris and Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural ...
Abivax Announces Former Prometheus COO, Mark Stenhouse, Appointed as B...
Abivax Announces Former Prometheus COO, Mark Stenhouse, Appointed as Board Observer & Advisor to Abivax Abivax Announces Former Prometheus COO, Mark Stenhouse, Appointed as Board Observer & Advisor to Abivax PARIS, France, November 13, 2024, 10:00 pm CET – Abivax SA (Euronext Paris and Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, today announced the appointment of Mark Stenhouse as Bo...
- Maissa Keskes
- Stephane Houri
TEMN TEMENOS AG
LEI LEIFHEIT AG
ITP INTERPARFUMS
IPH INNATE PHARMA SA CLASS A
VOE VOESTALPINE AG
TPE PVA TEPLA AG
SIX2 SIXT SE
WIE WIENERBERGER AG
TEG TAG IMMOBILIEN AG
DLG DE'LONGHI S.P.A.
JUN3 JUNGHEINRICH AG PREF
TKWY JUST EAT TAKEAWAY.COM N.V.
BSGR B&S GROUP S.A.
AG1 AUTO1 GROUP
SPAC 468 SPAC I SE
IOS IONOS GROUP SE
R3NK RENK GROUP AG
- Maissa Keskes
- Stephane Houri
TEMN TEMENOS AG
LEI LEIFHEIT AG
ITP INTERPARFUMS
IPH INNATE PHARMA SA CLASS A
VOE VOESTALPINE AG
TPE PVA TEPLA AG
SIX2 SIXT SE
WIE WIENERBERGER AG
TEG TAG IMMOBILIEN AG
DLG DE'LONGHI S.P.A.
JUN3 JUNGHEINRICH AG PREF
TKWY JUST EAT TAKEAWAY.COM N.V.
BSGR B&S GROUP S.A.
AG1 AUTO1 GROUP
SPAC 468 SPAC I SE
IOS IONOS GROUP SE
R3NK RENK GROUP AG
- Christophe-Raphaël Ganet
Interparfums : CMD and guidance: 2024 landing confirmed, cautious 2025...
>The management guides to 2025 growth of “just” 4%e - Ahead of its CMD today, Interparfums announced:1/ The fine tuning of its 2024 guidance: i/ 2024 sales are maintained in a range of between € 880-890m), ii/ the 2024 underlying operating margin is now projected to exceed 19%e, or >€ 170m est. (vs close to 19%, i.e. € 167-170m est. previously),2/ 2025 sales between € 910m and € 930m est. (i.e. +4% at the midpoint) , vs css >€ 950m est.;3/ A 2025 operat...
- Christophe-Raphaël Ganet
Interparfums : CMD et guidances : atterrissage 2024 conforté, perspect...
>Le management guide sur une croissance 2025 de « seulement » 4%e - En amont de son CMD, qui se tiendra aujourd’hui, Interparfums communique sur :1/ Le fine tuning de sa guidance 2024 : i/ le CA 24e est maintenu à une fourchette comprise entre 880-890 M€ précédemment), ii/ la MOp. courante 2024 devrait désormais dépasser les 19%e, soit >170 M€e (vs proche de 19% ie. 167-170 M€e jusqu’ici).2/ Un CA 2025 compris entre 910 et 930 M€e (ie. +4% en milieu de fourc...
- Mahaut Arnaud
- Paul de Froment
- Thomas Mordelle
Ebusco: strategic partnership with Gotion, launch of EUR36m rights iss...
Ebusco has announced a strategic partnership with Gotion, a company specialised in power battery technologies, building on their collaboration started in 2018. The partnership will focus on enhancing Ebusco's lightweight buses with Gotion's advanced battery tech, expanding into the Asian market, an
GTT: Monthly disclosure of the total number of voting rights and share...
GTT: Monthly disclosure of the total number of voting rights and shares composing the share capital Monthly disclosure of the total number of voting rights and shares composing the share capital Articles L. 233-8-II of the French Commercial Code and 223-16 of the General Regulation of the Autorité des Marchés Financiers Saint-Rémy-lès-Chevreuse, November 7, 2024 DateTotal number of sharesTheoretical total number of voting rights1Net total number of voting rights2October 31, 202437,117,77237,117,77237,049,337 Investor Relations Contact / 87 1 Calculat...
GTT : Information mensuelle relative au nombre total de droits de vote...
GTT : Information mensuelle relative au nombre total de droits de vote et d'actions composant le capital social Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social Articles L. 233-8-II du Code de commerce et 223-16 du Règlement général de l’Autorité des marchés financiers Saint-Rémy-lès-Chevreuse, le 7 novembre 2024 DateNombre total d’actions composant le capitalNombre total de droits de vote théoriques1Nombre total de droits de vote nets231 octobre 202437.117.77237.117.77237.049.337 Contact Relations Investisseurs : / 87 ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.